UK pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has updated data from the Phase III OlympiA study for its PARP inhibitor Lynparza (olaparib) at the San Antonio Breast Cancer Symposium 2024 (SABCS). The study provides significant insights into the efficacy and safety of Lynparza in patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer.
OlympiA Study Results and Clinical Impact
The OlympiA study demonstrated that Lynparza showed sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) at a median follow-up of 6.1 years for patients with high-risk early breast cancer. Lynparza reduced the risk of death by 28% (hazard ratio [HR] 0.72; 95% confidence interval [CI] 0.56-0.93) compared to placebo. Furthermore, it reduced the risk of invasive breast cancer recurrence, second cancers, or death by 35% (HR 0.65; 95% CI; 0.53-0.78) and the risk of distant disease recurrence or death by 35% (HR 0.65; 95% CI; 0.53-0.81) versus placebo. The benefits of Lynparza were consistent across all key subgroups, including patients with high-risk, hormone-receptor-positive disease. Its safety profile was consistent with previous findings.
Lynparza’s Global Approval and Impact
Lynparza, the first and only PARP inhibitor improving OS rate in breast cancer, is approved in multiple countries for use in ovarian cancer, fallopian tube cancer, prostate cancer, pancreatic cancer, peritoneal cancer, and more. Co-developed and commercialized by US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), the drug has treated over 140,000 patients worldwide, highlighting its significant impact on cancer treatment.-Fineline Info & Tech
Leave a Reply